An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian Cancer

Platinum resistant or refractory ovarian cancer

Bev+Pem: 19 patients, 68% w/ prior Bev; 95% w/ 2 or more prior therapies; Bev+PLD+Pem: 22 patients, median 3 prior therapies (1-13), 41% primary Pt-R, 82% w/ prior Bev, 41% w/ prior PARPi

Recurrence

Open-Label, Non-randomized

CBR, ORR, DCR, evaluated per RECIST

Bev+Pem:
ORR: 26.3% (1CR, 4PR, n=19) (not dependent on prior Bev therapy)
DCR: 78.9%
PFS: 4.7 months

Bev+PLD+Pem:
ORR: 31.6% (6PR, n=19)
DCR: 78.9% (6PR, 8SD, n=19)
CBR: 53%
PFS: 4.8 months

Bevacizumab+pembrolizumab with or without liposomal doxorubicin is well tolerated and demonstrate durable responses in platinum resistant ovarian cancer patients

Michels J et al. Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients. SITC (2021) abstract 355
https://jitc.bmj.com/content/9/Suppl_2/A382

Michels J et al. PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer. J Clin Oncol 40, 2022 (suppl 16; abstr 5575)
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.5575

Michels J et al. Poster
https://www.clearityfoundation.org/wp-content/uploads/2022/06/PEMBOV-poster-ASCO-2022-scaled.jpeg